Table 2. Multivariate cox regression for TTP and OS in all patients.
| Cox model* | Factors | HR (95% CI) | P |
|---|---|---|---|
| TTP | |||
| Gabor filter 0 Subgroups | TACE+sorafenib | 0.002 | |
| Gabor-1-90 ≤3.6190 | 0.802 (0.505–1.274) | ||
| Gabor-1-90 > 3.6190 | 2.184 (1.190–4.007) | ||
| Gabor filter 1. 0 Subgroups | TACE+sorafenib | 0.004 | |
| Gabor-1-135 ≤1.3995 | 0.455 (0.231–0.898) | ||
| Gabor-1-135 > 1.3995 | 1.298 (0.827–2.036) | ||
| Gabor filter 1.5 Subgroups | TACE+sorafenib | 0.008 | |
| Gabor-1-135 ≤0.5175 | 0.665 (0.390–1.137) | ||
| Gabor-1-135 > 0.5175 | 1.503 (0.930–2.431) | ||
| Wavelet Transform filter 1.0 Subgroups | TACE+sorafenib | 0.007 | |
| Wavelet-2-D ≤18.3585 | 0.663 (0.393–1.118) | ||
| Wavelet-2-D > 18.3585 | 1.486 (0.912–2.422) | ||
| Wavelet Transform filter 1.5 | None identified | ||
| OS | |||
| Wavelet Transform filter 1.0 Subgroups | TACE+sorafenib | 0.005 | |
| Wavelet-3-D < 12.2620 | 0.759 (0.465–1.239) | ||
| Wavelet-3-D > 12.2620 | 2.115 (1.101–4.062) | ||
Abbreviations:*Seven separate multivariate cox regression analyses were performed: 6 for TTP and 1 for OS, and only variables with a statistical significance were listed.
TTP: time to progression; OS: Overall survival; TACE: transcatheter arterial chemoembolization; HR: hazard ratio; BCLC: Barcelona Clinic Liver Cancer; VI/EM: vascular invasion or extrahepatic metastasis.